Research programme: antibody and protein-based therapeutics - Ambrx/Eli Lilly

Drug Profile

Research programme: antibody and protein-based therapeutics - Ambrx/Eli Lilly

Latest Information Update: 09 Jan 2014

Price : $50

At a glance

  • Originator Ambrx; Eli Lilly
  • Class Antibodies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported CNS disorders; Metabolic disorders

Most Recent Events

  • 09 Jan 2014 No development reported - Preclinical for CNS disorders in USA (Parenteral)
  • 09 Jan 2014 No development reported - Preclinical for Metabolic disorders in USA (Parenteral)
  • 23 Mar 2009 Preclinical trials in CNS disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top